TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01190813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tid
Study: NCT00325819
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
Study: NCT00350103
Drug: SPM 929
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Immediate release film-coated tablets~* Concentration: 50mg/ 100mg~* Route of administration: Oral use
Study: NCT00350103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Immediate release film-coated tablets~* Route of administration: Oral use
Study: NCT03291821
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analog subcutaneously
Study: NCT02801032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, matching capsule p.o. minimum one week apart from active treatment.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention.
Study: NCT02367547
Drug: Aminolevulinic Acid Nano Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the study we use Ameluz.
Study: NCT02367547
Drug: Methylaminolevulinate cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the study we use Metvix.
Study: NCT04020419
Drug: PediaBerry
Approvals — FDA: no, EMA: no, PMDA: no
Description: PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration
Study: NCT03257592
Drug: [11C]DPA-713
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[11C\]DPA-713 PET imaging
Study: NCT03842904
Drug: Trimbow pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Trial of an Investigational Medicinal Product (CTIMP)
Study: NCT03842904
Drug: Fostair pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Trial of an Investigational Medicinal Product (CTIMP)
Study: NCT04178304
Drug: Prolotherapy with 25% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose
Study: NCT00650819
Drug: Ezetimibe + Simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
Study: NCT00650819
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
Study: NCT00931203
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (400 mg/d) will be continued from day 1 to 65
Study: NCT03749317
Drug: IVIEW-1201
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days
Study: NCT03749317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days
Study: NCT04311710
Drug: ENHANZE (rHuPH20)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT03738423
Drug: REGN3500-Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneous (SC)
Study: NCT00435175
Drug: estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00532909
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
Study: NCT02315144
Drug: TV48108
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV48108 15, 60, 120 μg
Study: NCT02315144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT01000987
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00214617
Drug: Rosuvastatin at 5 mg/day and 40 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02844634
Drug: Doxycycline 100mg PO daily x 12 months
Normalized name: infigratinib
DrugBank: Infigratinib (DB11886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate use of daily doxycycline (12 months duration, to start immediately)
Study: NCT02844634
Drug: Doxycycline 100mg PO daily x 6 months
Normalized name: infigratinib
DrugBank: Infigratinib (DB11886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
Study: NCT04206657
Drug: 1mg KHK7580
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose administration of 1mg KHK7580
Study: NCT04206657
Drug: 3mg KHK7580
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose administration of 3mg KHK7580
Study: NCT04206657
Drug: 6mg KHK7580
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose administration of 6mg KHK7580
Study: NCT04206657
Drug: 12mg KHK7580
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose administration of 12mg KHK7580
Study: NCT04206657
Drug: 6mg KHK7580 for 8days
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral dose administration of 6mg KHK7580 for 8days
Study: NCT02382510
Drug: TRN-157
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00150410
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02906163
Drug: SoC (tyrosine kinase inhibitor)
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
Study: NCT01546051
Drug: BCI-1038, BCI-1206 & BCI-1283
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
Study: NCT03706157
Drug: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
Study: NCT02971384
Drug: Echinaforce
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05237115
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 40mg 1tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
Study: NCT04207177
Drug: Mycophenolate Mofetil 500 mg Tab
Normalized name: mycophenolate mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twice daily dosing of MMF only for a week before transplantation in this subgroup. All patients will get maintenance treatment With MMF in combination With tacrolimus and steroids after transplantation.
Study: NCT01899118
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825mg/m2 bid d1-5/w,1-5w
Study: NCT02105636
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05237115
Drug: Bacillus clotting
Approvals — FDA: no, EMA: no, PMDA: no
Description: given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
Study: NCT00288184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02256774
Drug: Combivir®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00434031
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00434031
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00163566
Drug: Dihydrotestosterone (0.7%) in hydroalcoholic gel
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
Study: NCT00356447
Drug: Estradiol/DRSP (Angeliq, BAY86-4891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
Study: NCT00356447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same administration.
Study: NCT00484471
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to aripiprazole, 22 weeks
Study: NCT00141518
Drug: Levodopa-carbidopa intestinal gel (LCIG)
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00410631
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00920153
Drug: ABVD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00410631
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00920153
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01333423
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
Study: NCT01425736
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
Study: NCT00400075
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00400075
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03250689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available as oval shaped, white film coated tablets.
Study: NCT03250689
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
Study: NCT03250689
Drug: Inhaled COPD maintenance medication
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist \[LAMA\], long-acting beta-agonist \[LABA\]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)
Study: NCT04331691
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
Study: NCT04331691
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
Study: NCT01625871
Drug: tablets artemether/lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: six doses of oral tablets of artemether/lumefantrine
Study: NCT00542893
Drug: Genasense® (G3139, oblimersen sodium)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00542893
Drug: Genasense followed by DTIC; then DTIC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
Study: NCT00542893
Drug: DTIC alone; then Genasense followed by DTIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
Study: NCT01749111
Drug: ARM B Calcineurin inhibitor and methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
Study: NCT01545388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match metformin 250 mg tablets, orally, for 24 weeks
Study: NCT00437164
Drug: Oral GW677954 Capsules (15 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01038687
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01807221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03093519
Drug: KHK6640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT03093519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT01619865
Drug: 68Ga-DOTATOC PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
Study: NCT00859222
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01737424
Drug: LC28-0126
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC28-0126
Study: NCT01737424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03207191
Drug: F16IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours
Study: NCT00001955
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00969826
Drug: GCPGC, Neulasta, Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
Study: NCT01406119
Drug: ABT-806
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-806 will be administered by intravenous infusion.
Study: NCT03307005
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule one per night taken for 7 nights
Study: NCT03670095
Drug: Lactose-free memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-free memantine tablet, 10 mg; orally as a single dose
Study: NCT00601315
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04488770
Drug: GSK3882347
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
Study: NCT04488770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching strength placebo capsules will be provided
Study: NCT04192214
Drug: BC 007
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1350 mg of BC 007
Study: NCT02162160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creme without probiotics applied in same manner
Study: NCT03468725
Drug: XPF-008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule filled with XEN1101
Study: NCT02664077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
Study: NCT01051479
Drug: C11-Choline
Normalized name: Choline C11
DrugBank: Choline C-11 (DB09563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
Study: NCT03224793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT03449251
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT03325335
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
Study: NCT00373295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01129245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical to celecoxib
Study: NCT02925858
Drug: Normal Saline Flush, 0.9% Injectable Solution_#1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion mimicking infusion rate of ketamine for a given weight
Study: NCT01026948
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
Study: NCT01718236
Drug: Succinylcholine + Neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
Study: NCT01012414
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02291289
Drug: FOLFOX induction regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per the Investigator's discretion in accordance with locally approved prescribing information.
Study: NCT04177043
Drug: DAAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with different regiments with DAAs
Study: NCT01127763
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00765856
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications
Study: NCT02571153
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline 0.9% 5 mL
Study: NCT04232345
Drug: AZD4831
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.
Study: NCT04232345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.
Study: NCT01944436
Drug: Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01715233
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 400mg/m2 on Day 1
Study: NCT01715233
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2
Study: NCT02198846
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
Study: NCT02936375
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1g/m², every 4 weeks, intravenous
Study: NCT02936375
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg/kg·d, once a day, orally administrated
Study: NCT02936375
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
Study: NCT04443647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray
Study: NCT00918593
Drug: Electrochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.